Pyrotinib, Trastuzumab, and Capecitabine

The combination of pyrotinib, trastuzumab, and capecitabine is a treatment regimen used primarily for HER2-positive metastatic breast cancer (MBC). This combination therapy represents a dual HER2 blockade approach, simultaneously targeting both the extracellular and intracellular domains of HER2[1]. Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that targets epidermal growth factor receptor, HER2, and HER4[4]. Trastuzumab is a monoclonal antibody that targets the extracellular domain of HER2. Capecitabine is an antimetabolite chemotherapy drug that gets broken down into fluorouracil in cells, which interferes with DNA and RNA synthesis[7]. ## Efficacy and Clinical Evidence This combination has shown promising efficacy in heavily pre-treated HER2-positive metastatic breast cancer patients, including those with brain metastases[1]. The dual HER2 blockade mechanism (using both pyrotinib and trastuzumab) has demonstrated synergistic effects in overcoming HER2 dependency in breast cancer models[8]. Research indicates that pyrotinib and trastuzumab together potentiate membrane HER2 ubiquitination and downregulation, resulting in comprehensive blockade of the HER2 signaling pathway[8]. Importantly, the pyrotinib-altered membrane HER2 levels do not significantly affect trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity (ADCC)[8]. ## Development Status The combination has been studied in clinical trials for HER2-positive metastatic breast cancer, particularly in patients who have previously been treated with trastuzumab or other therapies. The PHILA study demonstrated that pyrotinib, trastuzumab, and docetaxel significantly improved progression-free survival compared to placebo, trastuzumab, and docetaxel in patients with untreated HER2-positive metastatic breast cancer[8]. ## Safety Profile The combination therapy has shown a manageable safety profile in clinical studies. Common adverse events associated with pyrotinib-containing regimens include diarrhea and hand-foot syndrome, which are generally manageable with appropriate dose modifications[2][4]. This combination represents an important treatment option for patients with HER2-positive metastatic breast cancer, especially those who have progressed on previous therapies including trastuzumab.

Other names

Pyrotinib, SC Trastuzumab, and Capecitabine Neoadjuvant Therapy